Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
- Conditions
- Pancreatic NeoplasmsNeoplasmsEndocrine Gland NeoplasmsPancreatic DiseasesDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesEndocrine System DiseasesGemcitabineAntimetabolites, Antineoplastic
- Interventions
- Registration Number
- NCT01964430
- Lead Sponsor
- Celgene
- Brief Summary
The purpose of this study is to compare whether there is a delay or prevention of recurrence or death in participants with surgically removed pancreatic cancer who then take nab-Paclitaxel in combination with gemcitabine compared to those who take gemcitabine alone.
- Detailed Description
ABI-007-PANC-003 is a Phase 3, international, multicenter, randomized, open-label, controlled study that will compare the efficacy of nab-paclitaxel in combination with gemcitabine to gemcitabine alone as adjuvant treatment for 6 cycles in patients with surgically resected pancreatic adenocarcinoma.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 866
-
Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1). Subjects with neuroendocrine (and mixed type) tumors are excluded.
-
Pancreatic cancer surgical staging: Tumor (T) 1-3, Lymph Node (LN) N0-1, Metastasis (M) 0.
-
Subject should be able to start treatment no later than 12 weeks postsurgery.
-
≥18 years of age at the time of signing the informed consent form (ICF).
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
-
Acceptable hematology parameters:
- Absolute neutrophil count (ANC) ≥1500 cell/mm^3
- Platelet count ≥100,000/mm^3
- Hemoglobin (Hgb) ≥9 g/dL
-
Acceptable blood chemistry levels:
- Aspartate aminotransferase (AST)/ serum glutamic oxaloacetic transaminase (SGOT) and alanine transaminase (ALT)/ serum glutamic -pyruvic transaminase (SGPT) ≤2.5 × upper limit of normal range (ULN)
- Total bilirubin ≤ upper limit of normal (participants with Gilbert's syndrome can have bilirubin of up to 1.5 x ULN)
- Alkaline phosphatase ≤ 2.5 x ULN
- Serum creatinine within upper limits of normal or calculated clearance ≥50 mL/min/1.73 m^2. If using creatinine clearance, actual body weight should be used for calculating creatinine clearance (eg, using the Cockroft-Gault formula). For subjects with a body mass index (BMI) >30 kg/m2, lean body weight should be used instead
-
Cancer antigen (CA)19-9 <100 U/mL assessed within 14 days of randomization
-
Acceptable coagulation studies as demonstrated by prothrombin time (PT) and partial thromboplastin time (PTT) within normal limits (±15%)
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
-
Prior neo-adjuvant treatment or radiation therapy for pancreatic adenocarcinoma
-
Presence of or history of metastatic pancreatic adenocarcinoma
-
Any other malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix, uteri, or nonmelanomatous skin cancer (all treatment of which should have been completed 6 months prior to randomization)
-
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment
-
Known infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or subject receiving immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications
-
History of allergy or hypersensitivity to nab-paclitaxel or gemcitabine or any of their excipients
-
Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the subject's safety or the study data integrity. These include, but are not limited to:
- History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa)
- History of interstitial lung disease, slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies
- History of the following within 6 months prior to Cycle 1 Day 1: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or electrocardiogram (ECG) abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description nab-Paclitaxel 125 mg/m^2 plus gemcitabine 1000 mg/m2 nab-Paclitaxel Participants received nab-Paclitaxel 125 mg/m\^2 administered as an intravenous (IV) infusion over 30 to 40 minutes, followed by gemcitabine 1000 mg/m\^2 as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death. nab-Paclitaxel 125 mg/m^2 plus gemcitabine 1000 mg/m2 Gemcitabine Participants received nab-Paclitaxel 125 mg/m\^2 administered as an intravenous (IV) infusion over 30 to 40 minutes, followed by gemcitabine 1000 mg/m\^2 as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death. Gemcitabine 1000 mg/m^2 Gemcitabine Participants received gemcitabine 1000 mg/m\^2 administered as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death.
- Primary Outcome Measures
Name Time Method Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee Date of randomization up to data cut off date of 31 December 2018; median DFS follow-up time for censored participants was 22.242 months for nab-Paclitaxel and gemcitabine and 13.832 months for gemcitabine alone Disease free survival was defined as the time from the date of randomization to the date of disease recurrence or death, whichever occurred earlier. Disease recurrence was determined by the independent radiological review of computed tomography (CT) or magnetic resonance imaging (MRI) scans. Participants who did not have disease recurrence or did not die were censored at the last tumor assessment date with disease-free status or the randomization date if the last tumor assessment with disease-free status was missing. Disease-free status referred to a status that was neither being disease recurrent nor indeterminate or not evaluable. Participants who received new anti-cancer therapy or cancer-related surgery prior to disease recurrence or death were censored at the date of last tumor assessment with disease-free status prior to the start of new anti-cancer therapy or cancer-related surgery or the randomization date.
- Secondary Outcome Measures
Name Time Method Number of Participants With Treatment Emergent Adverse Events (TEAE's) From day 1 of study drug up to 28 days after the last dose of study drug; up to the data cut off date of 31 December 2018 (up to approximately 37 weeks). TEAEs are defined as any adverse event (AE) that begin or worsen on or after the start of study drug or procedure of the study period through the maximum duration of the period plus 28 days. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. Relation to study drug was determined by the investigator. A treatment-related TEAE is defined as TEAE which was considered to be related to one or both of the study drugs and reported as 'Suspected' on the case report form. AEs with a missing relationship were treated as 'treatment-related' in data summaries. IP (investigational product) refers to nab-Paclitaxel and/or Gemcitabine. "Related" TEAE refers to relation to study drug (IP).
The Number of Participants With Clinical Chemistry Laboratory-Detected Abnormalities (Grade 3-4) From day 1 of study drug up to 28 days after the last dose of study drug, or the treatment discontinuation date, whichever was later (up to approximately 37 weeks). The number of participants with grade 3-4 laboratory abnormalities in selected clinically significant parameters. Grades for chemistry parameters were coded using National Cancer Institute Common Terminology Criteria for Adverse Events (Grade 3= severe, Grade 4= life-threatening).
Kaplan Meier Estimate of Overall Survival (OS) From randomization to date of death; median OS follow-up time for censored participants was 77.832 months for nab-Paclitaxel and gemcitabine and 77.799 months for gemcitabine alone Overall survival was defined as the time from the date of randomization to the date of death. Participants who were alive at the end of study or clinical data cut were censored on the last-known-to-be-alive date or the clinical cutoff date, whichever was earlier.
Trial Locations
- Locations (341)
Local Institution - 016
🇺🇸Philadelphia, Pennsylvania, United States
Local Institution - 023
🇺🇸Chattanooga, Tennessee, United States
Local Institution - 010
🇺🇸Dallas, Texas, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Princess Margaret Hospital
🇨🇦Toronto, Ontario, Canada
Centro Integral
🇪🇸Madrid, Spain
State University of New York Upstate Medical Center
🇺🇸Syracuse, New York, United States
Roswell Park Cancer Institute
🇺🇸Buffalo, New York, United States
Case Western Reserve Center
🇺🇸Cleveland, Ohio, United States
Local Institution - 022
🇺🇸Boca Raton, Florida, United States
Florida Cancer Institute Cancer Spec
🇺🇸Fort Myers, Florida, United States
Local Institution - 032
🇺🇸New York, New York, United States
University of California Los Angeles
🇺🇸Santa Monica, California, United States
Local Institution - 025
🇺🇸Buffalo, New York, United States
Illinois Cancer Specialists
🇺🇸Niles, Illinois, United States
Local Institution - 066
🇺🇸Rockville Center, New York, United States
Local Institution - 064
🇺🇸Basking Ridge, New Jersey, United States
Local Institution - 050
🇺🇸Fort Worth, Texas, United States
Memorial Sloan-Kettering Cancer Center - NYC
🇺🇸New York, New York, United States
Local Institution - 013
🇺🇸Rochester, New York, United States
Local Institution - 054
🇺🇸Cleveland, Ohio, United States
University of Rochester Cancer Center, James P. Wilmot Cancer Center
🇺🇸Rochester, New York, United States
MSKCC at Phelps Memorial Hospital Center. Phelps Sleepy Hollow
🇺🇸Sleepy Hollow, New York, United States
Texas Oncology, P.A. - Tyler
🇺🇸Tyler, Texas, United States
Hospital Virgen del Rocio
🇪🇸Sevilla, Spain
Local Institution - 062
🇺🇸Dallas, Texas, United States
Texas Oncology
🇺🇸Dallas, Texas, United States
The Center for Cancer and Blood Disorders - Fort Worth
🇺🇸Fort Worth, Texas, United States
Local Institution - 507
🇦🇺St Leonards, New South Wales, Australia
ICON Cancer Center
🇦🇺Milton, Queensland, Australia
Austin Hospital
🇦🇺Heidelberg, Australia
Local Institution - 0271
🇩🇪Tübingen, Germany
Local Institution - 293
🇭🇺Budapest, Hungary
Klinikum der Universitat Munchen-Grosshadern
🇩🇪München, Germany
Local Institution - 282
🇩🇪München, Germany
Praxis Internistischer Onkologie und Hamatologie Koln
🇩🇪Köln, Germany
Universitatsklinikum Würzburg
🇩🇪Würzburg, Germany
Local Institution - 270
🇩🇪Würzburg, Germany
Azienda Ospedaliera Niguarda Ca Granda
🇮🇹Milano, Italy
Arcispedale Santa Maria Nuova
🇮🇹Reggio Emilia, Italy
Local Institution - 323
🇮🇹Roma, Italy
Fovarosi Szent Istvan es Szent Laszlo Korhaz es Rendelointezet
🇭🇺Budapest, Hungary
Local Institution - 329
🇮🇹Terni, Umbria, Italy
Local Institution - 642
🇰🇷Seoul, Korea, Republic of
Azienda Ospedaliero-Universitaria Careggi
🇮🇹Firenze, Italy
Local Institution - 328
🇮🇹Firenze, Italy
Petz Aladar Megyei Oktato Korhaz,II. Belgyogyaszat
🇭🇺Gyor, Hungary
Universitatsklinik Magdeburg
🇩🇪Magdeburg, Germany
Local Institution - 276
🇩🇪München, Germany
Klinikum der Johannes Gutenberg Uniervsitaet ,Haematologie
🇩🇪Mainz, Germany
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Szent-Gyorgyi Albert TE AOK Borgyogy
🇭🇺Szeged, Hungary
Azienda Ospedaliera S Maria di Terni
🇮🇹Terni, Italy
Uzsoki Utcai Korhaz
🇭🇺Budapest, Hungary
Klinikum Neuperlach
🇩🇪München, Germany
Local Institution - 640
🇰🇷Seoul, Korea, Republic of
Local Institution - 274
🇩🇪Magdeburg, Germany
Local Institution - 283
🇩🇪Mainz, Germany
Local Institution - 324
🇮🇹Pisa, Italy
Local Institution - 291
🇭🇺Budapest, Hungary
Hospital Da Luz
🇵🇹Lisboa, Portugal
National Cancer Center
🇸🇬Singapore, Singapore
Clinic Barcelona Hospital Universitari
🇪🇸Barcelona, Spain
Azienda Ospedaliera Universitaria Integrata di Verona
🇮🇹Verona, Italy
Local Institution - 295
🇭🇺Szeged, Hungary
Local Institution - 340
🇵🇹Lisboa, Portugal
Local Institution - 341
🇵🇹Lisboa, Portugal
Local Institution - 292
🇭🇺Gyor, Hungary
Local Institution - 403
🇳🇱Eindhoven, Netherlands
Local Institution - 361
🇪🇸Madrid, Spain
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Hospital General Gregorio Maranon
🇪🇸Madrid, Spain
Local Institution - 610
🇸🇬Singapore, Singapore
Local Institution - 625
🇨🇳Tainan, Taiana, Taiwan
Local Institution - 327
🇮🇹Roma, Italy
Local Institution - 641
🇰🇷Seoul, Korea, Republic of
Local Institution - 320
🇮🇹Verona, Italy
Local Institution - 371
🇪🇸Santander, Cantabria, Spain
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Local Institution - 363
🇪🇸Barcelona, Spain
Ramon y Cajal Univeresity Hospital
🇪🇸Madrid, Spain
Local Institution - 370
🇪🇸Barcelona, Spain
Hospital 12 de Octubre
🇪🇸Madrid, Spain
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Local Institution - 400
🇳🇱Amsterdam, Netherlands
Local Institution - 342
🇵🇹Porto, Portugal
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
Chang Gung Medical Foundation-Linkou Branch
🇨🇳Taoyuan, Taiwan
Local Institution - 362
🇪🇸Madrid, Spain
Local Institution - 369
🇪🇸Malaga, Spain
Centro Hospitalar de Lisboa Central - Hospital de Santo António dos Capuchos
🇵🇹Lisboa, Portugal
National University Hospital
🇸🇬Singapore, Singapore
Local Institution - 372
🇪🇸Madrid, Spain
Tri-Service General Hospital
🇨🇳Taipei, Taiwan
Addenbrookes Hospital
🇬🇧Cambridge, United Kingdom
Local Institution - 621
🇨🇳Tapei, Taiwan
Local Institution - 365
🇪🇸Madrid, Spain
Local Institution - 620
🇨🇳Taichung, Taiwan
Local Institution - 624
🇨🇳Taoyuan, Taiwan
Hospital Universitario Marques de Valdecilla
🇪🇸Santander, Spain
Local Institution - 382
🇬🇧Cambridge, United Kingdom
Local Institution - 366
🇪🇸Santiago De Compostela, Spain
National Cheng Kung University Hospital
🇨🇳Tainan, Taiana, Taiwan
Local Institution - 623
🇨🇳Taipei, Taiwan
Local Institution - 380
🇬🇧Glasgow, United Kingdom
Local Institution - 381
🇬🇧Sheffield, United Kingdom
Glasgow Royal Infirmary
🇬🇧Glasgow, United Kingdom
University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
Cleveland Clinic - Taussig Cancer Institute
🇺🇸Cleveland, Ohio, United States
Cleveland Clinic Foundation IRB
🇺🇸Cleveland, Ohio, United States
Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
Local Institution - 020
🇺🇸Cleveland, Ohio, United States
Local Institution - 005
🇺🇸Columbus, Ohio, United States
Ohio State University Medical Center
🇺🇸Columbus, Ohio, United States
Local Institution - 027
🇺🇸Pittsburgh, Pennsylvania, United States
UPMC Cancer Pavillion
🇺🇸Pittsburgh, Pennsylvania, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Local Institution - 045
🇺🇸Boston, Massachusetts, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Beth Israel-Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Baylor College of Medicine
🇺🇸Houston, Texas, United States
Local Institution - 003
🇺🇸Seattle, Washington, United States
Seattle Cancer Care Alliance - Seattle
🇺🇸Seattle, Washington, United States
Virginia Mason Cancer Center
🇺🇸Seattle, Washington, United States
University of Miami and Sylvester Cancer Center
🇺🇸Miami, Florida, United States
University of Cincinnati Medical CenterDivsion of Hematology OncologyThe Barrett Center
🇺🇸Cincinnati, Ohio, United States
Local Institution - 030
🇺🇸Cincinnati, Ohio, United States
Oncology Hematology Care, Inc.
🇺🇸Cincinnati, Ohio, United States
Local Institution - 241
🇫🇮Helsinki, Finland
Salzburger Landkliniken St. Johanns-Spital
🇦🇹Salzburg, Austria
Local Institution - 242
🇫🇮Turku, Finland
St Vincent's University Hospital
🇮🇪Dublin 4, Ireland
Academisch Medisch Centrum Amsterdam
🇳🇱Amsterdam, Netherlands
Catharina Hospital
🇳🇱Eindhoven, Netherlands
Isala Klinieken
🇳🇱Zwolle, Netherlands
Local Institution - 402
🇳🇱Zwolle, Netherlands
Local Institution - 508
🇦🇺Subiaco, Western Australia, Australia
Saint Barnabas Medical Center
🇺🇸Livingston, New Jersey, United States
University of California, San Francisco Cutaneous Oncology and Melanoma Center
🇺🇸San Francisco, California, United States
Local Institution - 004
🇺🇸Nashville, Tennessee, United States
Local Institution - 049
🇺🇸Oklahoma City, Oklahoma, United States
Local Institution - 002
🇺🇸Nashville, Tennessee, United States
Vanderbilt- Ingram Cancer Center
🇺🇸Nashville, Tennessee, United States
Karmanos Cancer Center Wayne State University
🇺🇸Detroit, Michigan, United States
Sarah Cannon Research Inst
🇺🇸Nashville, Tennessee, United States
University of Oklahoma Peggy and Charles Stephenson Cancer Center
🇺🇸Oklahoma City, Oklahoma, United States
Onk.Dep., Odense Universitets hospital
🇩🇰Odense C, Denmark
Local Institution - 326
🇮🇹Rozzano (MI), Italy
Rocky Mountain Cancer Centers, LLP [Denver-Midtown]
🇺🇸Denver, Colorado, United States
Local Institution - 019
🇺🇸Portland, Oregon, United States
Oregon Health and Science University OHSU
🇺🇸Portland, Oregon, United States
Local Institution - 275
🇩🇪Friedrichshafen, Germany
Hospital General Carlos Haya
🇪🇸Malaga, Spain
Local Institution - 367
🇪🇸Madrid, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Local Institution - 368
🇪🇸Pamplona/ Navarra, Spain
Hospital Clinico Universitario De Santiago De Compostela
🇪🇸Santiago De Compostela, Spain
University of Colorado Cancer Center
🇺🇸Aurora, Colorado, United States
Local Institution - 021
🇺🇸Rochester, Minnesota, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Nebraska Methodist Hospital
🇺🇸Omaha, Nebraska, United States
Instituto Catalan de Oncologia-Hospital Duran
🇪🇸Barcelona, Spain
H Lee Moffitt Cancer Center
🇺🇸Tampa, Florida, United States
Local Institution - 048
🇺🇸Omaha, Nebraska, United States
Georgia Cancer Specialist
🇺🇸Atlanta, Georgia, United States
Local Institution - 040
🇺🇸Boston, Massachusetts, United States
Local Institution - 321
🇮🇹Milano, Italy
Baylor Sammons Cancer Center
🇺🇸Dallas, Texas, United States
Saint Vincent's Hospital
🇦🇺Darlinghurst, Australia
Local Institution - 509
🇦🇺Heidelberg, Australia
Local Institution - 059
🇺🇸Denver, Colorado, United States
UCSD Moores Cancer Center
🇺🇸La Jolla, California, United States
Local Institution - 001
🇺🇸San Francisco, California, United States
Local Institution - 043
🇺🇸Scottsdale, Arizona, United States
Mayo Clinic - Arizona
🇺🇸Scottsdale, Arizona, United States
Lynn Cancer Institute
🇺🇸Boca Raton, Florida, United States
Local Institution - 031
🇺🇸Fort Myers, Florida, United States
Northshore University Healthsystem Research Institute
🇺🇸Evanston, Illinois, United States
MSKCC Basking Ridge
🇺🇸Basking Ridge, New Jersey, United States
Columbia University Medical Center
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center West Harrison
🇺🇸Harrison, New York, United States
NYU Langone Medical Center
🇺🇸Lake Success, New York, United States
Local Institution - 008
🇺🇸New York, New York, United States
MSKCC at Mercy Medical Center Mercy RockvilleCenter
🇺🇸Rockville Center, New York, United States
Local Institution - 047
🇺🇸Cleveland, Ohio, United States
Chattanooga Oncology Hematology Care
🇺🇸Chattanooga, Tennessee, United States
Local Institution - 038
🇺🇸Charlottesville, Virginia, United States
University of Virginia
🇺🇸Charlottesville, Virginia, United States
Local Institution - 041
🇺🇸Houston, Texas, United States
Local Institution - 501
🇦🇺Darlinghurst, New South Wales, Australia
Northern Cancer Institute
🇦🇺St Leonards, New South Wales, Australia
Local Institution - 502
🇦🇺Milton, Queensland, Australia
Local Institution - 504
🇦🇺Herston, Queensland, Australia
Local Institution - 506
🇦🇺Bentleigh East, Victoria, Australia
Monash Medical Centre Moorabbin Campus
🇦🇺Bentleigh East, Australia
St John of God Subiaco Hospital
🇦🇺Subiaco, Western Australia, Australia
Local Institution - 503
🇦🇺Malvern, Australia
Royal Brisbane and Women's Hospital
🇦🇺Herston, Australia
Cabrini Hospital
🇦🇺Malvern, Australia
Local Institution - 500
🇦🇺Randwick, Australia
Prince of Wales Hospital
🇦🇺Randwick, Australia
The Queen Elizabeth Hospital
🇦🇺Woodville South, Australia
Local Institution - 205
🇦🇹Graz, Austria
Medical University of Graz
🇦🇹Graz, Austria
Local Institution - 206
🇦🇹Linz, Austria
Local Institution - 203
🇦🇹Innsbruck, Austria
Medical University Innsbruck
🇦🇹Innsbruck, Austria
Hospital of Elisabethinen Linz
🇦🇹Linz, Austria
Local Institution - 204
🇦🇹Salzburg, Austria
Hospital Wiener Neustadt
🇦🇹Wiener Neustadt, Austria
Klinikum Wels-Grieskirchen GmbH
🇦🇹Wels, Austria
Local Institution - 202
🇦🇹Wiener Neustadt, Austria
Local Institution - 200
🇦🇹Wien, Austria
Medizinische Universitat Wien
🇦🇹Wien, Austria
Kaiser-Franz-Josef Spital
🇦🇹Wien, Austria
Local Institution - 201
🇦🇹Wien, Austria
Local Institution - 213
🇧🇪Gent, Belgium
Hopital Erasme
🇧🇪Brussels, Belgium
Local Institution - 211
🇧🇪Brussels, Belgium
UZ Antwerpen
🇧🇪Edegem, Belgium
Local Institution - 210
🇧🇪Leuven, Belgium
UZ Leuven
🇧🇪Leuven, Belgium
UZ Gent
🇧🇪Gent, Belgium
Local Institution - 102
🇨🇦Calgary, Alberta, Canada
Tom Baker Cancer Center
🇨🇦Calgary, Alberta, Canada
Local Institution - 101
🇨🇦Toronto, Ontario, Canada
Sunnybrook Health Sciences Centre
🇨🇦Toronto, Ontario, Canada
Local Institution - 100
🇨🇦Toronto, Ontario, Canada
Centre Hospitalier de L'Universite de Montreal St-Luc
🇨🇦Montreal, Quebec, Canada
Local Institution - 104
🇨🇦Montreal, Quebec, Canada
Local Institution - 103
🇨🇦Montreal, Quebec, Canada
Jewish General Hospital
🇨🇦Montreal, Quebec, Canada
Local Institution - 220
🇨🇿Hradec Kralove, Czechia
Krajska nemocnice Liberec, a.s.
🇨🇿Liberec, Czechia
Fakultni nemocnice Hradec Kralove
🇨🇿Hradec Kralove, Czechia
Local Institution - 221
🇨🇿Zlin, Czechia
Hæmatologisk afd. B Aalborg Sygehus Syd
🇩🇰Aalborg, Denmark
Local Institution - 231
🇩🇰Aalborg, Denmark
Krajska nemocnice T. Bati a.s.
🇨🇿Zlin, Czechia
Herlev Hospital
🇩🇰Herlev, Denmark
Tampereen yliopistollinen sairaala
🇫🇮Tampere, Finland
Local Institution - 232
🇩🇰Herlev, Denmark
Helsingin yliopistollinen keskussairaala
🇫🇮Helsinki, Finland
Local Institution - 240
🇫🇮Tampere, Oulun Lääni, Finland
Local Institution - 230
🇩🇰Odense C, Denmark
Turku University Hospital
🇫🇮Turku, Finland
Center Hospitalier Universitaire d' Angers
🇫🇷Angers cedex 09, France
Local Institution - 253
🇫🇷Angers cedex 09, France
CHRU de Lille France
🇫🇷Lille, France
Hopital Henri Mondor
🇫🇷Creteil, France
Local Institution - 257
🇫🇷Lille, France
Hopital Edouard Herriot - Hepato-gastroenterologie
🇫🇷Lyon Cedex 3, France
Local Institution - 258
🇫🇷Lyon Cedex 3, France
Hopital prive Jean Mermoz
🇫🇷Lyon, France
Local Institution - 252
🇫🇷Lyon, France
Hopital Europeen Georges Pompidou
🇫🇷Paris, France
Hopital Saint Antoine
🇫🇷Paris, France
Hopital Pitie Salpetriere
🇫🇷Paris, France
Local Institution - 250
🇫🇷Paris, France
Local Institution - 259
🇫🇷Paris, France
CHU La Miletrie
🇫🇷Poitiers Cedex, France
Local Institution - 251
🇫🇷Poitiers Cedex, France
Local Institution - 256
🇫🇷Toulose, France
Pole Des Specialites Medicales, Hopital Purpan
🇫🇷Toulose, France
Kliniken Essen-Mitte
🇩🇪Essen, Germany
Universitatsklinikum Carl Gustav Carus an der TU Dresden
🇩🇪Dresden, Germany
Klinikum Weiden
🇩🇪Bayern, Germany
Charite - Universitätsmedizin Berlin
🇩🇪Berlin, Germany
Local Institution - 280
🇩🇪Bayern, Germany
Local Institution - 272
🇩🇪Berlin, Germany
Local Institution - 278
🇩🇪Dresden, Germany
Universitatsklinkum Frankfurt
🇩🇪Frankfurt, Germany
Local Institution - 277
🇩🇪Frankfurt, Germany
Local Institution - 284
🇩🇪Frechen, Germany
Praxis Internistischer Onkologie und Hamatologie Frechen
🇩🇪Frechen, Germany
Ernst-Moritz-Arndt-Universität Greifswald
🇩🇪Greifswald, Germany
Praxis für Innere Medizin, Dr.Oettle Helmut
🇩🇪Friedrichshafen, Germany
Local Institution - 279
🇩🇪Greifswald, Germany
Local Institution - 273
🇩🇪Hamburg, Germany
Universitaetsklinik Hamburg - Eppendorf
🇩🇪Hamburg, Germany
Local Institution - 281
🇩🇪Köln, Germany
University of Tubingen
🇩🇪Tübingen, Germany
Prince of Wales Hospital the Chinese University of Hong Kong
🇭🇰Sha Tin, Hong Kong
Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum
🇭🇺Debrecen, Hungary
Local Institution - 290
🇭🇺Debrecen, Hungary
Local Institution - 310
🇮🇪Dublin 4, Ireland
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
🇭🇺Szolnok, Hungary
Local Institution - 311
🇮🇪Cork, Ireland
Local Institution - 325
🇮🇹Ancona, Italy
Ospedali Riuniti Umberto I GM Lancisi
🇮🇹Ancona, Italy
Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
🇮🇹Bologna, Italy
Local Institution - 330
🇮🇹Bologna, Italy
Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.)
🇮🇹Meldola, Italy
Local Institution - 322
🇮🇹Milano, Italy
Local Institution - 331
🇮🇹Meldola, Italy
Ospedale San Raffaele S.r.l.
🇮🇹Milano, Italy
Local Institution - 333
🇮🇹Reggio Emilia, Italy
Azienda Ospedaliero-Universitaria Pisana
🇮🇹Pisa, Italy
Istituto Clinico Humanitas
🇮🇹Rozzano (MI), Italy
IRCCS Casa Sollievo della Sofferenza
🇮🇹San Giovanni Rotondo, Italy
Local Institution - 332
🇮🇹San Giovanni Rotondo, Italy
Policlinico Universitario Agostino Gemelli
🇮🇹Roma, Italy
Istituto Nazionale Tumori Regina Elena
🇮🇹Roma, Italy
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Hospital de Sao Joao
🇵🇹Porto, Portugal
Local Institution - 611
🇸🇬Singapore, Singapore
Local Institution - 360
🇪🇸Barcelona, Spain
Complejo Hospitalario de Navarra
🇪🇸Pamplona/ Navarra, Spain
Local Institution - 364
🇪🇸Sevilla, Spain
Local Institution - 622
🇨🇳Taipei, Taiwan
Weston Park Hospital
🇬🇧Sheffield South Yorkshire, United Kingdom
National Taiwan University Hospital
🇨🇳Tapei, Taiwan
Memorial Sloan-Kettering Cancer Center
🇺🇸Commack, New York, United States
University of Southern California
🇺🇸Los Angeles, California, United States
Cork University Hospital
🇮🇪Cork, Ireland
Local Institution - 0207
🇦🇹Wels, Austria
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Canberra Hospital
🇦🇺Garran, Australian Capital Territory, Australia
Local Institution - 505
🇦🇺Garran, Australian Capital Territory, Australia
Local Institution - 044
🇺🇸Sacramento, California, United States
UC Davis Cancer Center
🇺🇸Sacramento, California, United States
Yale Cancer Center
🇺🇸New Haven, Connecticut, United States
Gainesville Heme Oncology Associates
🇺🇸Gainesville, Florida, United States
Local Institution - 011
🇺🇸Gainesville, Florida, United States
University of Florida
🇺🇸Gainesville, Florida, United States
Florida Hospital Cancer Institute
🇺🇸Orlando, Florida, United States
Local Institution - 039
🇺🇸Orlando, Florida, United States
University of Louisville
🇺🇸Louisville, Kentucky, United States
Ochsner Clinic Foundation
🇺🇸New Orleans, Louisiana, United States
Ochsner Medical Center - Jefferson Highway
🇺🇸New Orleans, Louisiana, United States
Local Institution - 036
🇺🇸Ann Arbor, Michigan, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
Local Institution - 051
🇺🇸Winston-Salem, North Carolina, United States
Wake Forest Univ. Health Sciences Outpatient Comprehensive Cancer Center
🇺🇸Winston-Salem, North Carolina, United States
Local Institution - 014
🇺🇸Madison, Wisconsin, United States
University of Wisconsin - Madison Cancer Center
🇺🇸Madison, Wisconsin, United States
Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States
Queen Mary Hospital
🇭🇰Hong Kong, Hong Kong
Tuen Mun Hospital
🇭🇰Hong Kong, Hong Kong
Local Institution - 601
🇭🇰Hong Kong, Hong Kong
Local Institution - 602
🇭🇰Sha Tin, Hong Kong